Wang Chunlei, Chen Sike, Caceres-Cortes Janet, Huang Richard Y-C, Tymiak Adrienne A, Zhang Yingru
Research & Development, Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, United States.
Research & Development, Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, United States.
J Chromatogr A. 2016 Jul 15;1455:133-139. doi: 10.1016/j.chroma.2016.05.086. Epub 2016 May 26.
UV spectrophotometry is widely used to determine the molar extinction coefficients (MECs) of cytotoxic drugs as well as the drug antibody ratios (DARs) of antibody drug conjugates (ADCs). However, the unknown purity of a drug due to interfering impurities can lead to erroneous MECs and DARs. Hence, reliable methods to accurately determine purity and the MECs of drugs with limited quantity is urgently needed in Drug Discovery. Such a method has been developed. It achieves absolute purity and accurate MEC determination by a single automated HPLC analysis that uses less than 5μg of material. Specifically, analytical HPLC separation with online UV detection was used to resolve impurities and measure absorbance from only the compound of interest. Simultaneously, an online chemiluminescence nitrogen detector (CLND) was used to determine the concentration of the analyte. The MECs were then calculated from the absorbance and concentration results. The accuracy of the method was demonstrated using caffeine and a commercial cytotoxic drug, DM1. This approach is particularly suited to analyzing mixtures or samples with low purities. Excellent reproducibility was demonstrated by analyzing a proprietary drug with linker synthesized from different batches with very different levels of purity. In addition, the MECs of drug with linker, along with ADC peak areas measured from size exclusion chromatography (SEC), were used to calculate DARs for 21 in-house ADCs. The DAR results were consistent with those obtained by MS analysis.
紫外分光光度法被广泛用于测定细胞毒性药物的摩尔消光系数(MEC)以及抗体药物偶联物(ADC)的药物抗体比(DAR)。然而,由于干扰杂质导致药物纯度未知,可能会导致错误的MEC和DAR。因此,药物研发中迫切需要可靠的方法来准确测定有限量药物的纯度和MEC。这样一种方法已经被开发出来。它通过单次自动高效液相色谱(HPLC)分析实现了绝对纯度和准确的MEC测定,该分析使用的材料少于5μg。具体而言,采用带有在线紫外检测的分析型HPLC分离来分离杂质,并仅测量目标化合物的吸光度。同时,使用在线化学发光氮检测器(CLND)来测定分析物的浓度。然后根据吸光度和浓度结果计算MEC。使用咖啡因和一种市售细胞毒性药物DM1证明了该方法的准确性。这种方法特别适合分析低纯度的混合物或样品。通过分析由不同批次合成的具有非常不同纯度水平的连接子的专利药物,证明了出色的重现性。此外,带有连接子的药物的MEC以及从尺寸排阻色谱(SEC)测得的ADC峰面积,被用于计算21种内部ADC的DAR。DAR结果与通过质谱分析获得的结果一致。